Regulatory perspectives of nanomedicines for cancer treatment

Abstract Nanomedicine is a novel and promising alternative technology that provides numerous advantages to conventional cancer therapies. It comes with early detection, improved treatment, and diagnosis of cancer. In spite of nanomedicines capability of delivering chemotherapeutic agents with lower systemic toxicity, it is important to first and foremost understand the complexity and dynamics of cancer for bridging the translational bench-to-bedside gap. Different techniques and skills should be deployed to explore the tumor microenvironment in order to achieve an all-inclusive understanding of the elementary biological processes in cancer and their contribution in regulating nanoparticle–protein interactions, blood circulation, and as well as tumor penetration. This chapter provides an overview of the current cancer nanomedicines and the future regulatory opportunities in this research area.